Vitamin E is the umbrella name for a family of fat-soluble antioxidants, the most important of which is alpha-tocopherol. Your body uses it to protect cell membranes from oxidative damage, especially in tissues that handle a lot of polyunsaturated fat, your brain, your liver, your red blood cells, and the LDL particles moving through your bloodstream.
Most people don't need to supplement it. Outright deficiency is rare in anyone eating a normal diet with seeds, nuts, vegetable oils, or leafy greens. Narrow contexts where supplemental vitamin E has been shown to do something useful, mainly fatty liver disease without diabetes, and a handful of skin and mucosal conditions where topical or oral tocopherol genuinely helps. Outside those contexts, the evidence for taking it as a daily "antioxidant for general health" is weak to neutral, and at high doses it actually carries downsides. This page is mostly about helping you figure out whether you're in one of the narrow contexts where it's worth taking, or whether you're better off getting it from food and moving on.
Deep-dive
Natural vitamin E is a family of eight related molecules, four tocopherols (alpha, beta, gamma, delta) and four tocotrienols (alpha, beta, gamma, delta). Alpha-tocopherol is the one your liver preferentially retains via the alpha-tocopherol transfer protein (α-TTP) and the one nearly all the clinical research uses. Gamma-tocopherol is more abundant in the typical Western diet (soybean and corn oil are high in it), has slightly different antioxidant chemistry, and gets aggressively cleared by the liver. The tocotrienols are mostly studied in cardiovascular and metabolic contexts but the human evidence is thin compared to alpha-tocopherol.
On labels you'll see "d-alpha-tocopherol" (natural, sometimes labelled RRR-alpha-tocopherol) and "dl-alpha-tocopherol" (synthetic, all-rac-alpha-tocopherol). The synthetic form is a mix of eight stereoisomers, only one of which is the form your α-TTP recognises well, so on a per-IU basis natural alpha-tocopherol delivers more usable vitamin E. Practically: 1 IU natural = 0.67 mg, 1 IU synthetic = 0.9 mg. Most clinical trials used natural-source d-alpha-tocopherol at 400-800 IU.
Fatty liver disease (NAFLD/NASH). This is the strongest indication for supplemental vitamin E and basically the only context where major hepatology guidelines recommend it. The pivotal trial is PIVENS, a 96-week randomised controlled trial in 247 non-diabetic adults with biopsy-confirmed NASH. 800 IU/day of natural alpha-tocopherol significantly improved liver histology (steatosis, lobular inflammation, hepatocyte ballooning) compared to placebo, with a higher rate of NASH resolution. Pioglitazone in the same trial didn't hit the primary endpoint. Fibrosis itself didn't reverse, but the underlying inflammatory drive did. Subsequent meta-analyses, including this one, have backed up the histological and enzyme improvements. The caveats are real: PIVENS excluded people with diabetes and cirrhosis, the paediatric TONIC trial failed to show sustained ALT reduction in children, and a separate signal from the SELECT trial suggested vitamin E may raise prostate cancer risk in older men (more on that below). If you have biopsy-confirmed NASH, no diabetes, no cirrhosis, and you're prepared to weigh the cancer signal, vitamin E is one of the few things with proper trial evidence behind it.
Cardiovascular disease. Despite decades of observational data linking higher vitamin E intake to lower heart disease rates, the randomised trials have been consistently disappointing. The Women's Health Study ran 39,876 healthy women for 10 years on 600 IU every other day and found no reduction in the primary cardiovascular endpoint, no reduction in cancer, and no reduction in total mortality (cardiovascular death dropped 24% as a secondary endpoint, but overall this is a null trial). The Physicians' Health Study II ran 14,641 men on 400 IU every other day for 8 years with the same result, no effect on major cardiovascular events. Meta-analyses have not just found no benefit, they've raised the possibility that doses above 400 IU/day modestly increase all-cause mortality. The clean reading is that supplemental vitamin E does not prevent heart disease in people who don't already have a problem, and the observational signal was probably a marker for general diet quality (fruits, vegetables, nuts) rather than the molecule itself.
Stroke. A 2010 meta-analysis of 9 trials in over 118,000 people found vitamin E slightly reduced ischaemic stroke (about 1 fewer per 476 people treated) but significantly raised haemorrhagic stroke (about 1 extra per 1250 treated). The two effects roughly cancel for total stroke. This is the most concrete safety signal in the literature and is the reason vitamin E shouldn't be stacked with anticoagulants or anti-platelet agents without medical supervision.
Cancer. The SELECT trial randomised 35,533 men to 400 IU/day of synthetic vitamin E, selenium, both, or placebo. After 7 years, the vitamin E group had a 17% increase in prostate cancer risk versus placebo. The absolute risk increase was small (76 vs 65 cases per 1000 men) but consistent and statistically significant. This effectively closed the door on vitamin E as a chemopreventive agent in healthy men and is the main reason guidance is more cautious now. Worth noting: SELECT used synthetic alpha-tocopherol, not natural, but it's not safe to assume natural is risk-free at the same dose.
Inflammation. A 2020 meta-analysis of randomised trials found vitamin E significantly lowered CRP across mixed populations (healthy adults, type 2 diabetes, NAFLD, CVD), with no effect on IL-6 or TNF-alpha. So the antioxidant story isn't entirely wrong, vitamin E does reduce one marker of systemic inflammation. It's just that this hasn't translated into meaningful clinical outcomes in healthy people.
Skin. Topical vitamin E for scars is mostly folklore. The most-cited trial found topical vitamin E either had no effect or worsened the cosmetic appearance of post-surgical scars in 90% of cases, and caused contact dermatitis in 33%. A systematic review found no convincing evidence vitamin E monotherapy improves scars, with consistent reports of contact dermatitis. Where it does have a role is as a co-ingredient in antioxidant serums alongside vitamin C and ferulic acid, which have evidence for photo-protection and post-procedure recovery. Bottom line: dabbing pure tocopherol oil on a scar is more likely to cause a rash than to help.
Women. Women metabolise alpha-tocopherol and gamma-tocopherol similarly to men, and the Women's Health Study is the largest single trial in this space. The cardiovascular signal in WHS was null for the primary endpoint, with a small subgroup benefit in women aged 65+ that has not been replicated. The PIVENS NASH evidence applies to women as well as men. There's no female-specific dose adjustment and no consistent menstrual-cycle effect. Pregnancy is a separate matter: dietary vitamin E intake is fine, but high-dose supplemental vitamin E in pregnancy has been linked to increased risk of pregnancy complications in some trials and is not recommended.
The big picture. Vitamin E is a useful nutrient with a narrow band of supplement-level evidence. It's a strong tool for biopsy-confirmed NASH in non-diabetic adults. It's a weak-to-null tool for cardiovascular prevention, cancer prevention, and general antioxidant support. It carries a real bleeding signal at higher doses and a real prostate cancer signal in older men. For most people, getting it from food (sunflower seeds, almonds, hazelnuts, sunflower oil, avocado, spinach) is the right answer.
Dosage:
- General supplementation (if you take it): 100-200 IU/day of natural d-alpha-tocopherol is the practical low-risk range. Above this you start running into the cardiovascular and cancer signals seen in trials
- NASH (biopsy-confirmed, non-diabetic, non-cirrhotic): 800 IU/day of natural d-alpha-tocopherol, the PIVENS dose. This is a treatment dose, not a general health dose, and should be discussed with a hepatologist. Recheck liver enzymes and clinical status at 6-12 months
- Don't exceed 400 IU/day long-term unless you have a specific clinical reason. Meta-analyses have flagged increased all-cause mortality and bleeding risk above this threshold
- Forms: Use natural d-alpha-tocopherol (sometimes labelled RRR-alpha-tocopherol) over synthetic dl-alpha-tocopherol (all-rac-). Natural is roughly 2x more bioavailable per IU. "Mixed tocopherols" products add gamma, delta, and beta forms and are closer to dietary intake, but the clinical trial data is overwhelmingly on alpha alone
- Timing: Take with a fat-containing meal. Vitamin E is fat-soluble and absorption is poor without dietary fat. No specific time of day matters
- Women in pregnancy or trying to conceive: Skip supplemental vitamin E. Dietary intake is fine, high-dose supplementation has shown harm signals in pregnancy trials
- Stacking: Avoid combining with anticoagulants (warfarin, DOACs) or anti-platelet drugs (aspirin, clopidogrel) without medical supervision, bleeding risk is additive. Avoid stacking with high-dose fish oil for the same reason if you're already on blood thinners. Vitamin E pairs sensibly with vitamin C and selenium from food, but adding all three as supplements doesn't have outcomes evidence behind it
Here's what you can expect:
For most people taking vitamin E as a general supplement, you should expect to feel nothing. There's no acute or subjective effect, no energy lift, no mood change. It's working at the level of membrane oxidation, which you can't perceive.
In NASH, the expected outcome is histological improvement on biopsy at 1-2 years and a fall in ALT and AST. You won't feel the difference directly, you'll see it on bloodwork and imaging.
For skin, expect nothing from pure topical tocopherol on scars or wounds, and a meaningful chance of contact irritation. The skin benefits of vitamin E are real but come from formulated antioxidant products (typically with vitamin C and ferulic acid), not from puncturing a capsule onto your face.
If you're taking it as insurance against heart disease or cancer, expect the same outcome as placebo. The randomised evidence is clear on this.
Side effects & risks:
- Bleeding is the most clinically relevant risk. Vitamin E inhibits platelet aggregation and interferes with vitamin K-dependent clotting factors at high doses. The risk goes up with anticoagulants and anti-platelet drugs and at doses above 400 IU/day. Stop supplementing 2 weeks before any planned surgery
- Haemorrhagic stroke risk is significantly elevated in meta-analysis, roughly 22% relative increase. The absolute risk is small but real and is the strongest reason not to take high doses long-term without a clinical indication
- Prostate cancer risk was raised 17% over 7 years in healthy older men on 400 IU/day synthetic alpha-tocopherol in the SELECT trial. If you're male, over 50, and have any family history of prostate cancer, the risk-benefit on chronic supplementation is poor
- All-cause mortality has shown a small but consistent increase in meta-analysis at doses above 400 IU/day. This is one of the most robust safety findings
- GI symptoms (nausea, diarrhoea, cramps) can occur at higher doses, typically above 1000 IU/day
- Contact dermatitis is common with topical vitamin E. If you develop a rash, redness, or itching where you've applied a product containing tocopherol, that's the likely culprit
- Drug interactions: Warfarin (raises INR and bleeding risk), aspirin and other antiplatelets, statins (vitamin E may partially blunt the HDL-raising effect of niacin/statin combinations), chemotherapy (some agents rely on oxidative damage, antioxidant interference is theoretical but worth flagging to your oncologist)
- Pregnancy: Skip supplemental vitamin E. Trials have flagged increased risk of pregnancy complications at supplemental doses, and dietary intake is adequate
- Heart failure: The HOPE-TOO trial showed a small but significant increase in heart failure hospitalisations in patients with vascular disease or diabetes on 400 IU/day. If you have existing heart failure or significant vascular disease, avoid supplemental vitamin E
- Long-term safety: The strongest safety data goes out to 7-10 years (SELECT, WHS, HOPE-TOO). Doses up to 400 IU/day are reasonably well-characterised over that period. The 800 IU PIVENS dose is well-characterised over 2 years but less so beyond
Blood markers
Baseline only if you're going on a treatment-level dose (400 IU+ daily). Most people taking 100-200 IU/day for general health don't need specific bloodwork.
ALT, AST, baseline and at 3-6 months if you're using vitamin E for NAFLD/NASH. The whole point of taking it in this context is to see liver enzymes normalise alongside histological improvement.
INR (if on warfarin) or platelet function (if on antiplatelets), baseline and at 4-6 weeks after starting. Vitamin E can shift coagulation and you want to catch it early.
PSA, baseline if you're male over 50 and considering chronic high-dose use, given the SELECT signal. Discuss with your doctor whether ongoing supplementation makes sense.
Lipid panel, baseline and at 3 months if you're taking it for cardiovascular reasons. Vitamin E doesn't reliably change lipids, but if you're spending money and accepting risk, you want to see if anything's actually moving.
For someone using vitamin E topically or eating a vitamin E-rich diet, no bloodwork is needed. Serum alpha-tocopherol can be measured but isn't useful in most clinical contexts outside of suspected deficiency (rare in anyone without fat malabsorption).
Sold as a dietary supplement in most countries without prescription.
Made with Bullet